Observational study / 2005
Cobalamin, MMA, and homocysteine levels fluctuated over time and failed to reliably predict or preclude cobalamin-responsive disorders in ambulatory patients.
Records of 456 ambulatory patients evaluated for cobalamin (Cbl) deficiency were reviewed. Pretherapy Cbl, methylmalonic acid (MMA), and homocysteine (HCys) values varied in individual patients by 23%, 23%, and 17%, respectively, over 2 to 6 weeks. Hematologic or neurologic responses to Cbl occurred in 37 of 95 evaluable patients, among whom pretherapy Cbl, MMA, and HCys levels were normal in 54%, 23%, and 50%, respectively. Among 25 non-responders, 45% had low Cbl, 45% had high MMA, and 43% had high HCys values, indicating these tests neither predicted nor precluded Cbl-responsive disorders.
Shows an association, not proof of cause and effect.
- Study type
- Retrospective chart review
- Who was studied
- 456 ambulatory patients evaluated for cobalamin deficiency at a staff model HMO
- What was measured
- Cobalamin, MMA, and HCys test reliability and clinical response to therapy
THE PAPER
Cobalamin-responsive disorders in the ambulatory care setting: unreliability of cobalamin, methylmalonic acid, and homocysteine testing.
Solomon LR. Blood, 2005.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.